

Cancer Monoclonal Antibodies Market Forecast to 2017

<https://marketpublishers.com/r/C3B540682ADEN.html>

Date: July 2013

Pages: 105

Price: US\$ 1,500.00 (Single User License)

ID: C3B540682ADEN

Abstracts

Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies.

Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. According to RNCOS' report, "Cancer Monoclonal Antibodies Market Forecast to 2017", the market for cancer mAbs is estimated at US\$ 24 Billion, and is expected to grow to around US\$ 34 Billion by 2017.

The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs.

In our report, we have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs.

Through our pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major

change in the market in terms of market share of current drugs.

Finally, RNCOS concludes its report with a competitive analysis of the major mAb players, providing brief descriptions of every player along with a list of current and pipeline mAbs. The report can therefore, provide assistance in evaluating the current market, discovering potential areas and analyzing the competitive environment.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. THE GLOBAL BURDEN OF CANCER

3.1 Cancer - A Leading Cause of Death

3.2 Current and Future Cancer Cases: By Type and Geography

3.3 Common Causes of Cancer

4. GLOBAL CANCER MARKET OUTLOOK TO 2017

4.1 Current and Future Growth

4.2 Analysis by Therapeutic Sub-Segments

5. MONOCLONAL ANTIBODIES: INTRODUCTION AND WORKING

5.1 Types of mAbs

5.1.1 Murine Antibodies

5.1.2 Chimeric and Humanized Antibodies

5.1.3 Fully Human Antibodies

5.2 Conjugated Cancer Therapies using mAbs

5.2.1 Radioimmunotherapy

5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)

5.2.3 Immunoliposomes

5.2.4 Immunotoxin

5.2.5 Immunocytokine

5.3 Cancer Monoclonal Antibody Therapies

5.3.1 Avastin (Bevacizumab)

5.3.2 Rituxan (Rituximab)

5.3.3 Herceptin (Trastuzumab)

5.3.4 Erbitux (Cetuximab)

5.3.5 Vectibix (Panitumumab)

5.3.6 Zevalin (Ibritumomab)

5.3.7 Bexxar (Tositumomab)

5.3.8 Xgeva (Denosumab)

5.3.9 Arzerra (Ofatumumab)

- 5.3.10 Yervoy (Ipilimumab)
- 5.3.11 Adcetris (Brentuximab Vedotin)
- 5.3.12 Perjeta (Pertuzumab)
- 5.3.13 Kadcyla (Ado-trastuzumab Emtansine)

6. INDUSTRY TRENDS AND DRIVERS

- 6.1 Strategic Activities or Alliances on Rise
- 6.2 New Clinical Approvals Showing Promising Future
- 6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
- 6.4 Antibody Drug Conjugates for Cancer Therapy

7. GLOBAL CANCER MABS MARKET OUTLOOK TO 2017

- 7.1 Market Size
- 7.2 Cancer mAbs: Approval History and Market Share
- 7.3 Cancer mAbs: Current and Future Market Size
 - 7.3.1 Avastin (Bevacizumab)
 - 7.3.2 MabThera/Rituxan (Rituximab)
 - 7.3.3 Herceptin (Trastuzumab)
 - 7.3.4 Erbitux (Cetuximab)
 - 7.3.5 Vectibix (Panitumumab)
- 7.4 Country-Level Analysis
 - 7.4.1 US
 - 7.4.2 Japan
 - 7.4.3 Europe
- 7.5 Market Share of Key Players

8. PIPELINE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES

9. COMPETITIVE LANDSCAPE

- 9.1 Roche
- 9.2 Eli Lilly
- 9.3 GlaxoSmithKline
- 9.4 Amgen
- 9.5 Bristol-Myers Squibb
- 9.6 Seattle Genetics
- 9.7 Spectrum Pharmaceuticals

9.8 Genmab

List Of Figures

LIST OF FIGURES:

- Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008
- Figure 3-2: Global - Number of Cancer Deaths (Million), 2008 & 2030
- Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020
- Figure 3-4: Global - New Cancer Cases by Region (%), 2009
- Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020
- Figure 4-1: Global - Pharmaceuticals Market by Therapy Areas (%), 2012 & 2017
- Figure 4-2: Global - Cancer Drugs Market (Billion US\$), 2012-2017
- Figure 4-3: Global - Cancer Drugs Market by Player (%), 2012
- Figure 4-4: Global - Cancer Drugs Market by Therapeutic Segment (%), 2012
- Figure 5-1: Types of Monoclonal Antibodies
- Figure 5-2: Hybridoma Technology for Mouse-derived Monoclonal Antibodies
- Figure 7-1: Global - Cancer mAbs Market (Billion US\$), 2012-2017
- Figure 7-2: Global - Cancer mAbs Market by Product (%), 2012
- Figure 7-3: Global - Avastin Sales (Billion US\$), 2012-2017
- Figure 7-4: Global - MabThera/Rituxan Sales (Billion US\$), 2012-2017
- Figure 7-5: Global - Herceptin Sales (Billion US\$), 2012-2017
- Figure 7-6: Global - Erbitux Sales (Billion US\$), 2012-2017
- Figure 7-7: Global - Vectibix Sales (Million US\$), 2012-2017
- Figure 7-8: Global - Cancer mAbs Market by Country/Region (%), 2012
- Figure 7-9: US - Cancer mAbs Market (Billion US\$), 2012-2017
- Figure 7-10: Japan - Cancer mAbs Market (Billion US\$), 2012-2017
- Figure 7-11: Europe - Cancer mAbs Market (Billion US\$), 2012-2017
- Figure 7-12: Global - Cancer mAbs Market by Player (%), 2012
- Figure 8-1: Global - Breakup of Cancer mAbs in Pipeline by Phase

List Of Tables

LIST OF TABLES:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)

Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)

Table 7-1: Global - List of FDA Approved Cancer mAbs with Year of Approval and Indication

Table 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2013)

Table 7-3: US - List of Approved Cancer mAbs with Year of Approval

Table 7-4: US - Cancer mAbs Expenditure in Clinics (Million US\$), 2011 & 2012

Table 7-5: Japan - Number of Cancer Deaths by Type and Gender (2010 & 2011)

Table 7-6: Japan - List of Approved Cancer mAbs with Year of Approval

Table 7-7: EU - Number of Cancer Cases and Deaths by Type (2012)

Table 7-8: EU - List of Approved Cancer mAbs with Year of Approval

Table 8-1: Global - Pipeline Analysis of Cancer mAbs

Table 8-2: Global - Number of Cancer mAbs in Pipeline by Type of Cancer

Table 9-1: Roche - Key Cancer Monoclonal Antibodies in Market

Table 9-2: Roche - Key Monoclonal Antibodies in Pipeline

Table 9-3: Eli Lilly - Key Cancer Monoclonal Antibodies in Market

Table 9-4: Eli Lilly - Key Cancer Monoclonal Antibodies in Pipeline

Table 9-5: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Market

Table 9-6: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Pipeline

Table 9-7: Amgen - Key Cancer Monoclonal Antibodies in Market

Table 9-8: Amgen - Key Cancer Monoclonal Antibodies in Pipeline

Table 9-9: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Market

Table 9-10: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Pipeline

Table 9-11: Seattle Genetics - Key Cancer Monoclonal Antibodies in Market

Table 9-12: Seattle Genetics - Key Cancer Monoclonal Antibodies in Pipeline

Table 9-13: Spectrum Pharmaceuticals - Key Cancer Monoclonal Antibodies in Market

Table 9-14: Genmab - Key Cancer Monoclonal Antibodies in Market

Table 9-15: Genmab - Key Cancer Monoclonal Antibodies in Pipeline

I would like to order

Product name: Cancer Monoclonal Antibodies Market Forecast to 2017

Product link: <https://marketpublishers.com/r/C3B540682ADEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3B540682ADEN.html>